Limits...
Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival.

Choi YL, Oh E, Park S, Kim Y, Park YH, Song K, Cho EY, Hong YC, Choi JS, Lee JE, Kim JH, Nam SJ, Im YH, Yang JH, Shin YK - BMC Cancer (2010)

Bottom Line: The results of this study showed that both TNBCs and BLBCs were associated with high histological and/or nuclear grades.After multivariate analysis of TNBCs, the BLBCs did not have a worse prognosis than the QNBC/5NPs.Interestingly, the patients with BLBCs showed significant adjuvant chemotherapy benefit.

View Article: PubMed Central - HTML - PubMed

Affiliation: Laboratory of Cancer Genomics and Molecular Pathology, Samsung Medical Center, Seoul, Korea.

ABSTRACT

Background: Triple-negative breast cancers (TNBCs) and basal-like breast cancers (BLBCs) are known as poor outcome subtypes with a lack of targeted therapy. Previous studies have shown conflicting results regarding the difference of prognostic significance between TNBCs and BLBCs. In this study, we aimed to characterize the prognostic features of TNBCs, in view of BLBCs and quintuple-negative breast cancers (QNBC/5NPs).

Methods: Using tissue microarray-based immunohistochemical analysis, we categorized 951 primary breast cancers into four or five subtypes according to the expression of ER, PR, HER2, and basal markers (CK5/6, EGFR).

Results: The results of this study showed that both TNBCs and BLBCs were associated with high histological and/or nuclear grades. When the TNBCs are divided into two subtypes by the presence of basal markers, the clinicopathologic characteristics of TNBCs were mainly maintained in the BLBCs. The 5-subgrouping was the better prediction model for both disease free and overall survival in breast cancers than the 4-subgrouping. After multivariate analysis of TNBCs, the BLBCs did not have a worse prognosis than the QNBC/5NPs. Interestingly, the patients with BLBCs showed significant adjuvant chemotherapy benefit. In addition, QNBC/5NPs comprised about 6~8% of breast cancers in publicly available breast cancer datasets

Conclusion: The QNBC/5NP subtype is a worse prognostic subgroup of TNBCs, especially in higher stage and this result may be related to adjuvant chemotherapy benefit of BLBCs, calling for caution in the identification of subgroups of patients for therapeutic classification.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier curves of disease-free survival and overall survival. Disease-free survival according to (A) four and (C) five IHC-based subtypes of breast cancers in the study subjects. Overall survival according to (B) four and (D) five subtypes of breast cancers in the study subjects (Estimated mean survival with 95% CI).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2957395&req=5

Figure 1: Kaplan-Meier curves of disease-free survival and overall survival. Disease-free survival according to (A) four and (C) five IHC-based subtypes of breast cancers in the study subjects. Overall survival according to (B) four and (D) five subtypes of breast cancers in the study subjects (Estimated mean survival with 95% CI).

Mentions: DFS time ranged from 0 to 152.1 months with median of 67.5 months. During the study period, 256 women (26.9% (256/951)) had local recurrence and/or metastasis. HR and 95% confidence intervals (95% CI) for DFS according to breast cancer subtypes are shown in Table 2 and survival analyses were demonstrated in Figure 1A and 1C. Advanced stage did not significantly increase the recurrence risk of luminal B and HER2 subtype (Table 2, Additional File 1, Figure S3). Interestingly, BLBCs showed obvious DFS benefit with adjuvant chemotherapy (HR, 0.24; 95% CI, 0.10-0.60; P = 0.002), whereas TNBCs did not show statistical benefit from chemotherapy.


Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival.

Choi YL, Oh E, Park S, Kim Y, Park YH, Song K, Cho EY, Hong YC, Choi JS, Lee JE, Kim JH, Nam SJ, Im YH, Yang JH, Shin YK - BMC Cancer (2010)

Kaplan-Meier curves of disease-free survival and overall survival. Disease-free survival according to (A) four and (C) five IHC-based subtypes of breast cancers in the study subjects. Overall survival according to (B) four and (D) five subtypes of breast cancers in the study subjects (Estimated mean survival with 95% CI).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2957395&req=5

Figure 1: Kaplan-Meier curves of disease-free survival and overall survival. Disease-free survival according to (A) four and (C) five IHC-based subtypes of breast cancers in the study subjects. Overall survival according to (B) four and (D) five subtypes of breast cancers in the study subjects (Estimated mean survival with 95% CI).
Mentions: DFS time ranged from 0 to 152.1 months with median of 67.5 months. During the study period, 256 women (26.9% (256/951)) had local recurrence and/or metastasis. HR and 95% confidence intervals (95% CI) for DFS according to breast cancer subtypes are shown in Table 2 and survival analyses were demonstrated in Figure 1A and 1C. Advanced stage did not significantly increase the recurrence risk of luminal B and HER2 subtype (Table 2, Additional File 1, Figure S3). Interestingly, BLBCs showed obvious DFS benefit with adjuvant chemotherapy (HR, 0.24; 95% CI, 0.10-0.60; P = 0.002), whereas TNBCs did not show statistical benefit from chemotherapy.

Bottom Line: The results of this study showed that both TNBCs and BLBCs were associated with high histological and/or nuclear grades.After multivariate analysis of TNBCs, the BLBCs did not have a worse prognosis than the QNBC/5NPs.Interestingly, the patients with BLBCs showed significant adjuvant chemotherapy benefit.

View Article: PubMed Central - HTML - PubMed

Affiliation: Laboratory of Cancer Genomics and Molecular Pathology, Samsung Medical Center, Seoul, Korea.

ABSTRACT

Background: Triple-negative breast cancers (TNBCs) and basal-like breast cancers (BLBCs) are known as poor outcome subtypes with a lack of targeted therapy. Previous studies have shown conflicting results regarding the difference of prognostic significance between TNBCs and BLBCs. In this study, we aimed to characterize the prognostic features of TNBCs, in view of BLBCs and quintuple-negative breast cancers (QNBC/5NPs).

Methods: Using tissue microarray-based immunohistochemical analysis, we categorized 951 primary breast cancers into four or five subtypes according to the expression of ER, PR, HER2, and basal markers (CK5/6, EGFR).

Results: The results of this study showed that both TNBCs and BLBCs were associated with high histological and/or nuclear grades. When the TNBCs are divided into two subtypes by the presence of basal markers, the clinicopathologic characteristics of TNBCs were mainly maintained in the BLBCs. The 5-subgrouping was the better prediction model for both disease free and overall survival in breast cancers than the 4-subgrouping. After multivariate analysis of TNBCs, the BLBCs did not have a worse prognosis than the QNBC/5NPs. Interestingly, the patients with BLBCs showed significant adjuvant chemotherapy benefit. In addition, QNBC/5NPs comprised about 6~8% of breast cancers in publicly available breast cancer datasets

Conclusion: The QNBC/5NP subtype is a worse prognostic subgroup of TNBCs, especially in higher stage and this result may be related to adjuvant chemotherapy benefit of BLBCs, calling for caution in the identification of subgroups of patients for therapeutic classification.

Show MeSH
Related in: MedlinePlus